ClinicalTrials.gg
CompletedNCT02788747Updated May 14, 2020Results posted

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

A Phase 2 interventional study of 4 mg elamipretide and 40 mg elamipretide in Heart Failure, sponsored by Stealth BioTherapeutics Inc.. Completed at 15 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-05-14.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 449 studies in Heart Failure with a site in Italy — 111 open to participants now, 130 under way, 18 of them phase 3. Heart Failure · Italy.

Enrollment
213th of 292
71 · median 200
Started
2016
with 16 others
Phase 2
38 of 449
none open now
Registered
194th of 449
by date

Among the 449 studies in Heart Failure with a site in Italy, this one is the 213th largest by enrollment of the 292 interventional ones that give a count, is one of 17 that started in 2016, is one of 38 in phase 2, and was the 194th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

111 of the 449 studies in Heart Failure with a site in Italy are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 449 studies in Heart Failure with a site in Italy, or all of them as a file.
02

Study summary

This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).

Read the detailed description

This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF). After completing the Screening period, a total of 71 subjects were randomized, in a 1:1:1 ratio, to receive either placebo, 4 mg elamipretide, or 40 mg elamipretide once daily for 28 consecutive days.

Each treatment group went through 3 distinct periods: Screening, Treatment, and Follow up.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide signed form (ICF) prior to participation in any study-related procedures.
  • Age ≥40 and ≤80 years.
  • A known history of chronic ischemic or non-ischemic cardiomyopathy of at least 6 months duration from the time of the initial diagnosis.
  • Receiving heart failure (HF) treatment, including, but not limited to, angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARB), and an evidence-based beta blocker for the treatment of HF. Subjects who cannot tolerate ACEI or ARB due to reduced renal function or hypotension are eligible. Subjects may be receiving aldosterone antagonists, but this is not a requirement for the study.
  • HF is considered to be stable in the judgment of the Investigator AND doses of HF treatment have been stable for at least 1 month prior to the Screening Visit.
  • In normal sinus rhythm ( documented) at Screening and Day 1 and no history of atrial fibrillation in the past 12 months
  • No hospitalization related to HF within 1 month prior to the Screening Visit.
  • (LVEF) ≤ 40% by 2-D echocardiography at Screening.
  • At least 3 viable segments (hyperenhancement ≤ 25%) by a qualifying delayed gadolinium-enhanced cardiac MRI examination at Screening (confirmed by independent core lab).
  • Women of must agree to use 1 of the following methods of from the date they sign the ICF until two months after the last dose of study medication:

    • Abstinence, maintenance of monogamous relationship with a male partner who has been surgically sterilized by vasectomy, or barrier method AND either hormonal contraception or an intrauterine device or system.

Exclusion criteria

Exclusion Criteria:

  • History of any concurrent medical condition which, in the opinion of the Investigator, significantly increased the potential risks associated with administration of study medication or any other aspect of study participation.
  • Any to MRI scanning.
  • Left ventricular end diastolic dimension (LVEDD) indexed to Body Surface Area is > 45 mm/m2.
  • Coronary or peripheral revascularization procedures, valvular procedures, OR any major surgical procedure within 3 months prior to the Screening Visit.
  • Acute coronary syndrome, stroke or (TIA) within 3 months prior to the Screening Visit.
  • Obstructive or restrictive cardiomyopathy, infiltrative diseases of the myocardium (e.g., amyloid, sarcoid, etc.) myocarditis, or reductions in LV function thought to be secondary primarily to valvular heart disease, prior cardiac valve surgery or known aortic stenosis.
  • The presence or anticipated placement of any pacemaker, implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy (CRT) devices during the ensuing 6-week study period.
  • Presence of second degree or advanced heart block.
  • Uncontrolled hypertension defined as a systolic blood pressure > 160 mmHg or a diastolic blood pressure > 110 mmHg on at least two consecutive readings.
  • Presence of any left ventricular thrombus, pericardial disease, uncorrected thyroid disease or a dyskinetic left ventricular aneurysm.
  • History of cancer that causes symptoms, disabilities, or is likely to lead to hospitalization or treatment in the next 12 months.
  • Currently receiving treatment with chemotherapeutic agents or agents or has received prior radiation therapy to the chest.
  • Liver enzymes ( [ALT] AND/OR aspartate. aminotransferase [AST]) elevation > 3 times the (ULN).
  • Total > 1.5 times ULN in the absence of Gilbert's Syndrome.
  • Bleeding diathesis or any known blood dyscrasia.
  • Anemia, defined as \< 9 g/dL or planned blood transfusions in the next 6 weeks.
  • Estimated (eGFR) \< 30 mL/min, using the Modification of Diet in Renal Disease (MDRD) Study equation.
  • History of , or (HIV) infection, or diagnosis of immunodeficiency.
  • Known active drug or alcohol abuse within 1 year of the Screening Visit. Alcohol abuse is defined as 15 or more drinks for men per week or 8 or more for women.
  • Recipient of any drugs, stem cell or gene therapies, or devices OR participation in another clinical trial, within 3 months prior to the Screening Visit.
  • Female subjects who are pregnant, planning to become pregnant, or lactating.
  • Requiring any change in doses of cardiovascular medication (including diuretics) in order to control worsening of HF symptoms.
  • Known allergy to gadolinium.
  • Currently receiving treatment with therapeutic doses of anticoagulants. Antiplatelet therapy used to prevent cardiovascular disease (primary prevention) or to treat chronic disease (secondary prevention) is permitted.
  • Currently receiving treatment with sacubitril/valsartan or trimetazidine.
  • Hyponatremia defined as plasma Na+ level \<125 mEq/L (UK only).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    4 mg elamipretide

    4 mg elamipretide once daily for 28 consecutive days

    Drug: 4 mg elamipretide

  • Experimental
    40 mg elamipretide

    40 mg elamipretide once daily for 28 consecutive days

    Drug: 40 mg elamipretide

  • Placebo comparator
    Placebo

    Placebo once daily for 28 consecutive days

    Drug: Placebo

Interventions

  • Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days

    Also known as: MTP-131, Bendavia

  • Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days

    Also known as: MTP-131, Bendavia

  • DrugPlacebo

    Subcutaneous injection of placebo administered once daily for 28 consecutive days

06

What researchers measure

Primary outcomes

  1. Change in Left Ventricular End Systolic Volume (ml)

    Change in left ventricular end systolic volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Change in Left Ventricular Ejection Fraction (% of Blood Volume)

    Change in Left Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  2. Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI

    Change from baseline in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  3. Change in Left Ventricular Stroke Volume (ml)

    Change in Left Ventricular Stroke Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  4. Change in Left Ventricular Cardiac Output (L/Min)

    Change in Left Ventricular Cardiac Output as measured by L/min from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  5. Change in Left Ventricular Myocardial Mass (g)

    Change in Left Ventricular Myocardial Mass as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  6. Change in Right Ventricular End Systolic Volume (mL)

    Change in Right Ventricular End Systolic Volume as measured by mL from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  7. Change in Right Ventricular End Diastolic Volume (mL)

    Change in Right Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  8. Change in Right Ventricular Ejection Fraction (% Blood Volume)

    Change in Right Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

    Time frame: Baseline to Week 4

  9. Change in Early and Late Mitral Inflow Velocity Ratio

    Change in Early and Late Mitral Inflow Velocity Ratio from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  10. Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')

    Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio as measured by E/e' from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  11. Change in Left Atrial Volume (mL)

    Change in Left Atrial Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  12. Change in Left Ventricular Global Longitudinal Strain Assessment (%)

    Change in Left Ventricular Global Longitudinal Strain Assessment as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  13. Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography

    Change in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  14. Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography

    Change in Left Ventricular End Systolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  15. Change in Biplane Ejection Fraction (mL)

    Change in Biplane Ejection Fraction as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  16. Left Ventricular Mass Assessment (g)

    Change in Left Ventricular Mass Assessment as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  17. Change in Tricuspid Regurgitation Severity Assessment (cm²)

    Change in Tricuspid Regurgitation Severity Assessment as measured by cm from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  18. Change in Right Ventricular Fractional Area (%)

    Change Right Ventricular Fractional Area in as measured by percentage from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  19. Change in Right Ventricular Systolic Pressure (mmHg)

    Change in Change in Right Ventricular Systolic Pressure as measured by mmHg from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

  20. Change in Mitral Regurgitation Severity (cm²)

    Change in Mitral Regurgitation Severity as measured by cm² from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

    Time frame: Baseline to Week 4

07

Results

Posted Apr 22, 2020

Participant flow

Participant flow — Overall Study
Milestone4 mg Elamipretide40 mg ElamipretidePlacebo
Started232424
Completed222424
Not completed100
Withdrew: Adverse event100

Outcome measures

PrimaryChange in Left Ventricular End Systolic Volume (ml)

Change in left ventricular end systolic volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Left Ventricular End Systolic Volume (ml)
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular End Systolic Volume (ml)-4.4 ± 6.50-1.2 ± 9.04-3.8 ± 5.85
SecondaryChange in Left Ventricular Ejection Fraction (% of Blood Volume)

Change in Left Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · percentage of blood volume
Change in Left Ventricular Ejection Fraction (% of Blood Volume)
percentage of blood volume4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular Ejection Fraction (% of Blood Volume)2.2 ± 2.431.5 ± 2.822.3 ± 3.69
SecondaryChange in Left Ventricular End Diastolic Volume (ml) as Measured by MRI

Change from baseline in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI-2.8 ± 9.500.5 ± 11.96-2.2 ± 9.77
SecondaryChange in Left Ventricular Stroke Volume (ml)

Change in Left Ventricular Stroke Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Left Ventricular Stroke Volume (ml)
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular Stroke Volume (ml)3.1 ± 9.233.7 ± 9.363.0 ± 13.14
SecondaryChange in Left Ventricular Cardiac Output (L/Min)

Change in Left Ventricular Cardiac Output as measured by L/min from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · L/min
Change in Left Ventricular Cardiac Output (L/Min)
L/min4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular Cardiac Output (L/Min)0.21 ± 1.264-0.01 ± 1.0040.27 ± 0.860
SecondaryChange in Left Ventricular Myocardial Mass (g)

Change in Left Ventricular Myocardial Mass as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · grams
Change in Left Ventricular Myocardial Mass (g)
grams4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular Myocardial Mass (g)0.0 ± 2.82-0.4 ± 2.78-0.0 ± 2.26
SecondaryChange in Right Ventricular End Systolic Volume (mL)

Change in Right Ventricular End Systolic Volume as measured by mL from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Right Ventricular End Systolic Volume (mL)
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Right Ventricular End Systolic Volume (mL)-0.9 ± 4.21-0.8 ± 4.94-0.6 ± 3.72
SecondaryChange in Right Ventricular End Diastolic Volume (mL)

Change in Right Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Right Ventricular End Diastolic Volume (mL)
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Right Ventricular End Diastolic Volume (mL)0.5 ± 9.70-1.2 ± 10.72-0.0 ± 7.61
SecondaryChange in Right Ventricular Ejection Fraction (% Blood Volume)

Change in Right Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.

Time frame:
Baseline to Week 4
Reported as:
Mean · percentage of blood volume
Change in Right Ventricular Ejection Fraction (% Blood Volume)
percentage of blood volume4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Right Ventricular Ejection Fraction (% Blood Volume)1.4 ± 3.050.4 ± 2.101.2 ± 3.33
SecondaryChange in Early and Late Mitral Inflow Velocity Ratio

Change in Early and Late Mitral Inflow Velocity Ratio from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · ratio
Change in Early and Late Mitral Inflow Velocity Ratio
ratio4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Early and Late Mitral Inflow Velocity Ratio-0.04 ± 0.185-0.03 ± 0.329-0.07 ± 0.528
SecondaryChange in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')

Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio as measured by E/e' from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · ratio
Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')
ratio4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')-0.94 ± 3.2440.47 ± 4.359-0.20 ± 4.287
SecondaryChange in Left Atrial Volume (mL)

Change in Left Atrial Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Left Atrial Volume (mL)
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Atrial Volume (mL)-3.4 ± 6.85-0.2 ± 4.411.6 ± 4.02
SecondaryChange in Left Ventricular Global Longitudinal Strain Assessment (%)

Change in Left Ventricular Global Longitudinal Strain Assessment as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · percentage of myocardial length change
Change in Left Ventricular Global Longitudinal Strain Assessment (%)
percentage of myocardial length change4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular Global Longitudinal Strain Assessment (%)-1.76 ± 1.993-1.50 ± 2.721-1.46 ± 2.362
SecondaryChange in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography

Change in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography-1.1 ± 16.291.6 ± 13.682.0 ± 15.29
SecondaryChange in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography

Change in Left Ventricular End Systolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography-1.9 ± 11.59-0.5 ± 7.910.6 ± 10.31
SecondaryChange in Biplane Ejection Fraction (mL)

Change in Biplane Ejection Fraction as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · mL
Change in Biplane Ejection Fraction (mL)
mL4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Biplane Ejection Fraction (mL)1.8 ± 2.942.0 ± 2.821.5 ± 4.22
SecondaryLeft Ventricular Mass Assessment (g)

Change in Left Ventricular Mass Assessment as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · grams
Left Ventricular Mass Assessment (g)
grams4 mg Elamipretide40 mg ElamipretidePlacebo
Left Ventricular Mass Assessment (g)3.0 ± 18.26-4.2 ± 18.55-0.7 ± 21.99
SecondaryChange in Tricuspid Regurgitation Severity Assessment (cm²)

Change in Tricuspid Regurgitation Severity Assessment as measured by cm from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · cm²
Change in Tricuspid Regurgitation Severity Assessment (cm²)
cm²4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Tricuspid Regurgitation Severity Assessment (cm²)-1.03 ± 1.3340.25 ± 1.336-0.30
SecondaryChange in Right Ventricular Fractional Area (%)

Change Right Ventricular Fractional Area in as measured by percentage from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · percentage of area
Change in Right Ventricular Fractional Area (%)
percentage of area4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Right Ventricular Fractional Area (%)0.1 ± 10.820.1 ± 8.790.9 ± 8.93
SecondaryChange in Right Ventricular Systolic Pressure (mmHg)

Change in Change in Right Ventricular Systolic Pressure as measured by mmHg from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · mmHg
Change in Right Ventricular Systolic Pressure (mmHg)
mmHg4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Right Ventricular Systolic Pressure (mmHg)5.7 ± 16.19-1.5 ± 6.63-7.0 ± 25.61
SecondaryChange in Mitral Regurgitation Severity (cm²)

Change in Mitral Regurgitation Severity as measured by cm² from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.

Time frame:
Baseline to Week 4
Reported as:
Mean · cm²
Change in Mitral Regurgitation Severity (cm²)
cm²4 mg Elamipretide40 mg ElamipretidePlacebo
Change in Mitral Regurgitation Severity (cm²)0.70 ± 2.668-0.71 ± 2.200-0.73 ± 1.834

Adverse events

Collected over 10 weeks (The AE reporting period began when the subject signed the ICF and continued through the clinical study's post treatment follow-up period, defined as 14 days after last administration of study medication.). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
4 mg Elamipretide0/22 (0%)0/22 (0%)9/22 (40.9%)
40 mg Elamipretide0/25 (0%)1/25 (4%)16/25 (64%)
Placebo0/24 (0%)0/24 (0%)10/24 (41.7%)
Most frequent serious events
Most frequent serious events
Event4 mg Elamipretide40 mg ElamipretidePlacebo
VestibularNervous system disorders0/221/250/24
Most frequent other events
Showing 10 of 40
Most frequent other events
Event4 mg Elamipretide40 mg ElamipretidePlacebo
FatigueGeneral disorders2/221/251/24
NasopharyngitisInfections and infestations1/222/251/24
DizzinessNervous system disorders1/221/251/24
HeadacheNervous system disorders1/220/250/24
Injection site haemorrhageGeneral disorders1/220/250/24
ConstipationGastrointestinal disorders1/220/250/24
NauseaGastrointestinal disorders1/220/251/24
Renal impairmentRenal and urinary disorders1/220/250/24
Pain in extremityMusculoskeletal and connective tissue disorders1/220/250/24
Gastroenteritis viralInfections and infestations1/220/250/24

Baseline characteristics

Of the 22 subjects in the 4 mg group, 1 subject (1.4%) discontinued from the study due to an AE. One of the subjects randomized to 4mg elamipretide arm was treated with 40mg elamipretide.

Age, Continuous
Age, Continuous(years)4 mg Elamipretide40 mg ElamipretidePlaceboTotal
Mean65.3 ± 10.7662.6 ± 9.6366.8 ± 9.0764.8 ± 9.83
Sex: Female, Male
Sex: Female, Male(Participants)4 mg Elamipretide40 mg ElamipretidePlaceboTotal
Female35917
Male19201554
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)4 mg Elamipretide40 mg ElamipretidePlaceboTotal
Hispanic or Latino0101
Not Hispanic or Latino22242470
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)4 mg Elamipretide40 mg ElamipretidePlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White22252471
More than one race0000
Unknown or Not Reported0000
Left ventricular end systolic volume
Left ventricular end systolic volume(mL)4 mg Elamipretide40 mg ElamipretidePlaceboTotal
Mean87.0 ± 38.4579.6 ± 21.5477.7 ± 38.5881.3 ± 33.28
08

Study locations

15 sites
  • A.O. Papa Giovanni XXIII Cardiologia 1, Torre 5
    Bergamo, 24127, Italy
  • A.O. Spedali Civili di Brescia Cardiologia
    Brescia, 25123, Italy
  • Azienda Ospedaliera Brotzu Cardiologia
    Cagliari, 09134, Italy
  • Centro Cardiologico Monzino U.O. Scompenso, Cardiologia Clinica e Cardiologia Riabilitativa
    Milano, 20138, Italy
  • Ospedale Niguarda Ca' Granda SC Cardiologia 2
    Milano, 20162, Italy
  • Cardiologia clinica, Unità dello Scompenso e Terapia intensive Reparto Carlo Magno, Faggi Policlinico di Monza
    Monza, 20900, Italy
  • Dip. Cardiotoracovascolare: Cardiologia Fondazione IRCCS Policlinico San Matteo Pad. Nuovo Ospedale "DEA" Degenza: PIANO +3 Ambulatori: P.T. e P+3
    Pavia, 27100, Italy
  • Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanità Pubblica
    Pisa, 56124, Italy
  • Deventer Hospital, Department of Cardiology
    Deventer, 7416 SE, Netherlands
  • University Medical Centre Groningen
    Groningen, 9713 GZ, Netherlands
  • Anthonius Ziekenhuis, Cardiology Department
    Sneek, 8601 ZK, Netherlands
  • Elisabeth Twee Steden Hospital (ETZ), Department of Cardiology
    Tilburg, 5022 GC, Netherlands
  • Gelre Ziekenhuis Zutphen, Department of Cardiology
    Zutphen, 7207 AE, Netherlands
  • Ninewells Hospital and Medical School
    Dundee, DDI 9SY, United Kingdom
  • William Harvey Heart Centre CRC, (Barts Health NHS Trust)
    London, EC1M 6BQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Sep 2017, 15 months.

Results were first posted in Apr 2020, 2 years 7 months after primary completion.

Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 15 months is below that.

Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2016
First posted
Jun 2, 2016
StartActual
Jun 2016
Primary completionActual
Sep 2017
CompletionActual
Oct 2017
Results first posted
Apr 22, 2020
Last update
May 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02788747
Responsible party
Sponsor
First posted
Jun 2, 2016
Start date
Jun 2016
Primary completion
Sep 2017
Completion
Oct 2017
Results posted
Apr 22, 2020
Last update
May 14, 2020

Study contacts

Gerasimos Filippatos, MD
study chair · University of Athens, School of Medicine, Athens, Greece

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion